ALK is a gene that can fuse with others genes to form a “gene fusion product” that promotes the growth of non-small cell lung cancer (NSCLC). For example, about 5 percent of NSCLC patients have a fusion of ALK with a gene called EML4.
In this study, researchers are evaluating an investigational drug called LDK378 in patients with NSCLC who have an ALK gene fusion and whose cancer has continued to grow despite therapy. LDK378 is designed to inhibit the cancer-promoting activity of the ALK gene fusion product. LDK378 is a capsule that is taken orally (by mouth).